Jeena Sikho — An Ayurveda Roll-Up in a Hurry

The State of Play

Jeena Sikho Lifecare runs a fast-growing chain of Ayurvedic hospitals and clinics (the “Shathayu” network) and sells Ayurvedic medicines — and through FY26 it grew at a pace that is rare in healthcare: full-year revenue up ~71% to ₹801 crore, profit to ₹222 crore, on eye-popping operating margins (44% for the year, individual quarters printing 45–48%). It is a promoter-driven story — founder Acharya Manish Grover is the brand’s face and voice on every call — moving on many fronts at once: adding beds, launching over-the-counter products, signing distribution and diagnostics tie-ups, migrating to the main board, and floating a long-term vision of ₹1,000 crore in profit. It is also a story where several of management’s own promises have moved or slipped, which makes the quarter-by-quarter record worth reading carefully.

The Company

Jeena Sikho operates Ayurvedic and naturopathy hospitals, clinics and day-care centres across 23 states and 100-plus cities, alongside an Ayurvedic products/medicines business. Revenue splits three ways internally: in-hospital treatment (“private Panchakarma”), government-panel treatment (CGHS/RGHS/employee schemes), and product/medicine sales. In FY25 those were roughly ₹136 crore, ₹118 crore and ₹215 crore of a ₹469 crore total. The model has two unusual features for a hospital company: very high gross margins (product gross margin ~85%; treatment ARPOB ~₹8,300 a bed-day, far below a typical allopathic hospital but on a much lighter cost base), and a deliberately capital-light expansion thesis.

It is tightly promoter-controlled — Grover holds the brand’s public identity, and promoter holding sits at ~63.6% (down from a ~68% peak). Returns are extraordinary on paper (ROCE ~64%, ROE ~61%) on a small equity base; the stock trades at ~35 times earnings (₹7,829 crore market cap). The company listed via a small SME IPO in 2022 and migrated to the NSE/BSE main board in August 2025, switching to quarterly reporting and Ind-AS accounting at the same time. (A note on what the data does not corroborate: the screener snapshot doesn’t carry the “Shathayu/Sukhayu” brand names or a separate product-sales line, and only two annual reports — FY24 and FY25 — were retrievable; FY23 and FY22 reports failed to download.)

The Story So Far

The two annual reports (FY24, FY25) and four calls (Q4 FY25 through Q3 FY26) trace a company scaling fast and constantly revising its own targets upward.

The base (FY24–FY25, from the annual reports)

FY24 revenue was ₹324 crore (+59%), with the product business the larger leg (57% products / 43% services), ~1,277 beds, and a maiden dividend. FY25 revenue grew 45% to ₹469 crore, and the mix flipped to services-led (54% services / 46% products) as the hospital business grew 83%; in-patient admissions nearly doubled to ~24,500. Beds reached 2,173 on paper. The FY25 report set out the ambition that the calls would keep enlarging: ~3,000 beds in FY26 and 8,000–10,000 over five years, an OTC product launch, and a UAE foray. (One structural caution the reports never list as a risk: the business leans heavily on Grover’s personal visibility — a single-promoter, key-man dependence.)

Q4/FY25 (call of 20 May 2025) — the targets are set

The last half-yearly call before quarterly reporting laid out the plan. FY25 had closed at ₹469 crore revenue and ₹90.7 crore profit — though Grover noted this missed an earlier ₹100 crore profit “guidance,” blaming front-loaded costs from ~500 beds added in the final three months (“the expense has come this time and the profit will come this time”). He guided to ~₹720 crore FY26 revenue and a 20% (stretch 23–25%) profit margin. Crucially, he introduced the capital-light pivot: rather than build its own hospitals, Jeena Sikho would take over the ~100-bed hospitals attached to India’s hundreds of Ayurvedic colleges on rent-plus-revenue-share, claiming a cost of ~₹1 lakh per bed versus ₹2.5–3.5 lakh to build — underpinning a 7,000–10,000 bed, five-year target. An overhang also surfaced: trade receivables had jumped to ₹98 crore, almost all government, on a 3–8 month payment cycle.

Q1 FY26 (call of 18 August 2025) — main-board debut, OTC launch

The first quarterly call showed revenue up 74% to ₹174 crore and profit tripling to ₹51 crore at a 45% EBITDA margin. Two strategic moves landed: the OTC products business officially launched on 22 August (a “Pet Yakrit Pleeha Shuddhi” liver kit at ₹960 that, management said, sold its first batch out in four days), and the government-receivables problem turned into a deliberate exit — government work was cut from ~24% of revenue to ~8%, with private patients and health insurance taking its place. Grover was explicit that the 45% EBITDA margin was “a lottery, not the base,” reiterating 20–25% PAT as the real target. Governance churn began: E&Y, named as auditor in May, was dropped for Grant Thornton.

Q2 FY26 (call of 7 November 2025) — diagnostics and distribution tie-ups

Revenue grew 66% to ₹190 crore, margin to ~48%. The bed target of ~2,800 was hit in six months (2,802) — but with a persistent catch: only ~2,200 were operational, the rest awaiting registrations, and occupancy stayed at 57%. Two partnerships defined the quarter: a Chandan Diagnostics tie-up (Chandan funds all lab capex inside Jeena Sikho centres, splitting commission) aimed at lifting footfall and insurance claims, and advanced talks with Entero, a B2B pharma distributor reaching ~1.25 lakh pharmacies, for an exclusive Ayurveda distribution deal. Government work was cut further to ~3–4%. There was visible investor tension on the calls — one analyst argued the company was leaving money on the table by shrinking its government business, which Grover firmly rejected on cash-cycle grounds.

Q3 FY26 (call of 9 February 2026) — the ₹1,000 crore vision

The seasonally weakest quarter produced the first ₹100 crore-plus EBITDA quarter (revenue ₹222 crore, +92%; profit ₹66.7 crore, +405%). The OTC flagship crossed ₹10 crore a month, a second product (NutriRoz) was launching, and the Entero exclusive deal was finalised. Here the guidance ratcheted decisively: FY26 profit was now framed at ”~₹225 crore+” (versus the ₹125–130 crore guided just a quarter earlier), and Grover floated a long-term target of ₹1,000 crore in profit over three to four years — built on 15 mass-need products (each ~₹10 crore a month) plus 7,000–10,000 beds at ~50% occupancy. Governance kept upgrading (Forvis Mazars added as internal auditor; Salesforce and Oracle implementations). The operational-versus-built bed gap persisted: ~2,290 beds operational of ~2,800 built, with management choosing not to switch on ~500 beds in a weak season.

How the promises tracked

The honest reconciliation, which is the point of a chronicle here:

• FY26 profit: guided ₹125–130 crore (Q2) → raised to ”~₹225 crore+” (Q3) → the year closed at ₹222 crore. Delivered against the raised number.
• But Q4 gave back margin: the March 2026 quarter softened — revenue dipped to ₹216 crore and operating margin fell to 36% (from a 48% September peak), profit dropping to ₹45 crore — a reminder that the 45–48% prints were not a stable base, exactly as Grover had cautioned.
• Beds: the 2,800 target was hit early, but occupancy stayed stuck at 53% → 57% → 57% → 58%, against a repeatedly promised “70–80% in 6–8 months,” because ~500 built beds were never made operational.
• The capital-light college model under-delivered: three tie-ups announced in FY25 were still just three (one operational) by Q3, with a ~16-college pipeline paused; the cost-per-bed claim drifted from “₹1 lakh via colleges” back to the standard ₹3–4 lakh.
• Government exit and OTC ramp: both delivered as described (government cut from ~24% to ~3%; OTC from launch to ₹10 crore/month).
• Governance: main-board migration, a Big-Four-tier statutory auditor (Grant Thornton) and internal auditor (Forvis Mazars) all delivered — though a CEO hire promised since 2024 remained open (only a COO appointed).

Where Things Stand

As of the February 2026 call, Jeena Sikho is a high-growth, high-margin, promoter-driven Ayurveda business compounding revenue at 60–90% a quarter, with genuine operating momentum (OTC scaling, insurance acceptance rising, diagnostics and distribution tie-ups signed) and an unusually light balance sheet for a hospital company. It is also a business whose narrative runs ahead of its delivered operations in places: occupancy on its growing bed base has stayed in the high-50s despite repeated “70–80%” promises, the headline EBITDA margin is volatile (and management itself flags 20–25% PAT as the real base, borne out by the softer March quarter), the much-touted capital-light college model has so far under-delivered, and the targets have ratcheted upward faster than a single year can test. The forward markers management has set — a ₹1,000 crore profit vision, 7,000–10,000 beds, 15 OTC products, in-house manufacturing, a possible “high-level acquisition” — are large and numerous, and the value of reading this chain of quarters is precisely that it lets the next few calls be checked against them. For a stock at ~35 times earnings, that follow-through is the whole question.

The Four Checks

1. Quality and moat. A genuinely profitable business, but the moat is mostly one man’s brand. What Jeena Sikho has is the founder’s personal trust franchise — Acharya Manish Grover’s face on TV and social media — sitting on top of a network that claims roughly 8–9% of India’s NABH-accredited AYUSH hospitals, in a fragmented, “largely unregulated” industry (the FY24 report’s own words). The protective layers are real but thin: NABH accreditation, insurance empanelment with a dozen-plus insurers, and now an exclusive Entero distribution deal. Against that, the OTC formulations can be copied (management admits this — the claimed moat is “customer trust”), key-man dependence on a single promoter is never even listed as a risk in two annual reports, and the company’s narrative has repeatedly run ahead of delivery (occupancy stuck in the high-50s against promised 70–80%, the capital-light college model stalled at three tie-ups). Call it a decent business with a brand edge, contestable on every flank.

2. Returns on incremental capital and runway. The printed returns are extraordinary — ROCE 64%, ROE 61% on the June 2026 snapshot — and they are not an accident of a tiny base alone: the franchise-heavy model pushes capex onto partners, products carry ~85% gross margins, and fixed assets of ₹294 crore support ₹801 crore of revenue. The trend is down from FY24’s even-more-extraordinary 80% ROCE, which is the normal arithmetic of a growing equity base, not deterioration. The runway claim is enormous (8,000–10,000 beds, 15 OTC products, a ₹1,000 crore profit vision), but the evidence on redeployment is mixed: the college model that was supposed to deliver beds at ₹1 lakh apiece drifted back to ₹3–4 lakh, and roughly 500 built beds sat dark for three straight quarters. High returns on what has been deployed so far; the repeatability at 4–5x the size is unproven.

3. Capital allocation for the stage. Broadly rational, with scatter. The good: growth has been funded almost entirely from internal accruals and a small ₹55.5 crore SME IPO — no fresh equity since 2022, borrowings of just ₹127 crore against ₹442 crore of reserves, free cash flow of ₹221 crore in FY26, and a dividend that has stepped up to a 25% payout. No buyback history exists to judge. The questionable: the company is sprinting on many fronts at once — UAE, Nepal, Kazakhstan, a diagnostics tie-up, super-specialty clinics, a planned manufacturing buy, and cash deliberately hoarded for an unnamed “high-level acquisition” — exactly the pattern that turns a focused compounder into a conglomerate of enthusiasms. Promoters have also trimmed from ~68% to ~63.6%. Disciplined on the balance sheet, undisciplined in the number of simultaneous bets.

4. Price. Demanding. As of the June 2026 snapshot the stock trades at ₹600 — a ₹7,451 crore market cap, 33.6 times FY26 earnings and 15.9 times book — on a year in which profit nearly tripled and operating margin hit 44%. The catch is that management itself calls 20–25% PAT the real base, not the 45–48% EBITDA quarters, and the March 2026 quarter duly gave margin back (36% OPM, profit down to ₹45 crore from ₹67 crore). If the sustainable margin is what Grover says it is, the multiple is being paid on earnings near a cyclical-seasonal peak. A buyer at this price is underwriting the ₹1,000 crore profit vision, high-50s occupancy finally reaching 70–80%, and fifteen OTC products each doing what one has done so far — a lot of follow-through for a multiple that already assumes it.

Sources

• Earnings-call transcripts read (4): Q4/FY25 (20 May 2025, the last half-yearly call), Q1 FY26 (18 Aug 2025), Q2 FY26 (7 Nov 2025), Q3 FY26 (9 Feb 2026). From screener/BSE-hosted filings. (No Q4 FY26 results call was available at fetch time; FY26 full-year figures are from the financial snapshot.)
• Annual reports read: FY24, FY25 only — FY23 and FY22 reports failed to download, so the multi-year arc is shorter than usual and leans on the FY25 report’s restated comparatives.
• Financial snapshot: screener.in (JSLL), logged-out session, fetched 2026-06-07 — the source for FY26 full-year figures (revenue ₹801 crore, PAT ₹222 crore) and the softer March-2026 quarter.
• Research dump: vault/Sources/Earnings/Jeena Sikho Lifecare Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.